EarningsAptar’s first-quarter results beat expectations on profitability, and second-quarter EPS guidance exceeded forecasts.
Financial PerformancePharma continues to perform well, showing year-over-year growth and margin improvement despite macroeconomic challenges.
Growth PotentialImproving ROIC should support multiple expansion, with a five-year EPS CAGR expected to be upwards of 10%, combined with a roughly 1% dividend as an attractive total shareholder return.